Neovacs is focused on the development of Kinoids, therapeutic vaccines for the treatment of autoimmune and inflammatory diseases and cancer.
Business Model:
Revenue: $0
Employees: 11-50
Address: 3-5, Impasse Reille
City: Paris
State: other
Zip: 75014
Country: FR
Neovacs is focused on the development of Kinoids, therapeutic vaccines for the treatment of autoimmune and inflammatory diseases and cancer.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2021 | Signia Therapeutics | Series A | 1.5M |
9/2021 | Bio-Detection K9 | Venture Round | 0 |
10/2021 | Signia Therapeutics | Series A | 0 |
9/2021 | Bio-Detection K9 | Venture Round | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2015 | Post-IPO Equity | $8.4M | 6/2021 | Post-IPO Debt | $4.8M | 2/2021 | Post-IPO Debt | 1 | $1.2M |
Alpha Blue Ocean™ Alpha Blue Ocean™ |
7/2017 | Post-IPO Equity | $7.1M | 7/2007 | Venture Round | 2 | $17.9M |
Novartis Venture Fund Truffle Capital Novartis Venture Fund Novartis Venture Fund Truffle Capital Novartis Venture Fund |
6/2005 | Venture Round | 1 | - |
Debiopharm Innovation Fund Debiopharm Innovation Fund Debiopharm Innovation Fund Debiopharm Innovation Fund |
1/2016 | Post-IPO Equity | 1 | $5.4M |
Bpifrance Bpifrance |
7/2017 | Private Placement | $7.1M | 1/2016 | Investment Fund | $5.4M | 6/2005 | Venture Round | 1 | - |
Debiopharm Innovation Fund Debiopharm Innovation Fund Debiopharm Innovation Fund Debiopharm Innovation Fund |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|